259 related articles for article (PubMed ID: 28655764)
1. Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.
Dogan T; Gnad F; Chan J; Phu L; Young A; Chen MJ; Doll S; Stokes MP; Belvin M; Friedman LS; Kirkpatrick DS; Hoeflich KP; Hatzivassiliou G
J Biol Chem; 2017 Sep; 292(35):14311-14324. PubMed ID: 28655764
[TBL] [Abstract][Full Text] [Related]
2. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
4. Regulation of neuronal survival and morphology by the E3 ubiquitin ligase RNF157.
Matz A; Lee SJ; Schwedhelm-Domeyer N; Zanini D; Holubowska A; Kannan M; Farnworth M; Jahn O; Göpfert MC; Stegmüller J
Cell Death Differ; 2015 Apr; 22(4):626-42. PubMed ID: 25342469
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis.
Liu Q; Tao B; Liu G; Chen G; Zhu Q; Yu Y; Yu Y; Xiong H
J Biol Chem; 2016 Feb; 291(9):4779-92. PubMed ID: 26724804
[TBL] [Abstract][Full Text] [Related]
6. Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.
Trotta AP; Gelles JD; Serasinghe MN; Loi P; Arbiser JL; Chipuk JE
J Biol Chem; 2017 Jul; 292(28):11727-11739. PubMed ID: 28546431
[TBL] [Abstract][Full Text] [Related]
7. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function.
Liu S; Yamauchi H
Cancer Lett; 2009 Dec; 286(2):240-9. PubMed ID: 19631451
[TBL] [Abstract][Full Text] [Related]
8. Cdh1, a substrate-recruiting component of anaphase-promoting complex/cyclosome (APC/C) ubiquitin E3 ligase, specifically interacts with phosphatase and tensin homolog (PTEN) and promotes its removal from chromatin.
Choi BH; Pagano M; Huang C; Dai W
J Biol Chem; 2014 Jun; 289(25):17951-9. PubMed ID: 24811168
[TBL] [Abstract][Full Text] [Related]
9. Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.
Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B
Cell Cycle; 2014; 13(20):3302-11. PubMed ID: 25485510
[TBL] [Abstract][Full Text] [Related]
10. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
[TBL] [Abstract][Full Text] [Related]
11. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
[TBL] [Abstract][Full Text] [Related]
12. Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1.
Wan L; Zou W; Gao D; Inuzuka H; Fukushima H; Berg AH; Drapp R; Shaik S; Hu D; Lester C; Eguren M; Malumbres M; Glimcher LH; Wei W
Mol Cell; 2011 Dec; 44(5):721-33. PubMed ID: 22152476
[TBL] [Abstract][Full Text] [Related]
13. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
14. Effect of ursolic acid on MAPK in cyclin D1 signaling and RING-type E3 ligase (SCF E3s) in two endometrial cancer cell lines.
Achiwa Y; Hasegawa K; Udagawa Y
Nutr Cancer; 2013; 65(7):1026-33. PubMed ID: 24083669
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
16. Akt activation by Ca
Gocher AM; Azabdaftari G; Euscher LM; Dai S; Karacosta LG; Franke TF; Edelman AM
J Biol Chem; 2017 Aug; 292(34):14188-14204. PubMed ID: 28634229
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis.
Shah M; Stebbins JL; Dewing A; Qi J; Pellecchia M; Ronai ZA
Pigment Cell Melanoma Res; 2009 Dec; 22(6):799-808. PubMed ID: 19712206
[TBL] [Abstract][Full Text] [Related]
18. A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-Cdk2 during cell cycle progression.
Sørensen CS; Lukas C; Kramer ER; Peters JM; Bartek J; Lukas J
Mol Cell Biol; 2001 Jun; 21(11):3692-703. PubMed ID: 11340163
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
20. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
